• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异柠檬酸脱氢酶1/2（IDH1/IDH2）突变型急性髓系白血病的疾病特征与监测

Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia.

作者信息

Dantec Mélinda, Dufossé Maxime, Boudry Augustin, Fournier Elise, Goursaud Laure, Lebon Delphine, Bories Claire, Plantier Isabelle, Tricot Sabine, Daniel Adrien, Willaume Alexandre, Coiteux Valérie, Berthon Céline, Marolleau Jean-Pierre, Preudhomme Claude, Duployez Nicolas, Fenwarth Laurène

机构信息

Laboratory of Hematology, Biology and Pathology Center, CHU Lille, Lille, France.

University of Lille, U1277-Canther, INSERM, Lille, France.

出版信息

Blood Cancer J. 2025 May 23;15(1):101. doi: 10.1038/s41408-025-01304-x.

DOI:10.1038/s41408-025-01304-x
PMID:40410134
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12102383/
Abstract

[Image: see text]

摘要

[图像：见正文]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4953/12102383/ea2d71a6f47e/41408_2025_1304_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4953/12102383/63ab422c9c81/41408_2025_1304_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4953/12102383/ea2d71a6f47e/41408_2025_1304_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4953/12102383/63ab422c9c81/41408_2025_1304_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4953/12102383/ea2d71a6f47e/41408_2025_1304_Fig2_HTML.jpg

相似文献

1
Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia.异柠檬酸脱氢酶1/2（IDH1/IDH2）突变型急性髓系白血病的疾病特征与监测
Blood Cancer J. 2025 May 23;15(1):101. doi: 10.1038/s41408-025-01304-x.
2
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.异柠檬酸脱氢酶突变型急性髓系白血病患者接受异基因造血细胞移植的结局。
Transplant Cell Ther. 2021 Jun;27(6):479.e1-479.e7. doi: 10.1016/j.jtct.2021.02.028. Epub 2021 Feb 25.
3
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.新诊断的急性髓系白血病患者中异柠檬酸脱氢酶 1 和 2（IDH1 和 IDH2）代谢基因的分子改变和其他基因突变。
J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5.
4
Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.急性髓系白血病中 IDH1/2 突变患者的其他突变。
Int J Lab Hematol. 2021 Dec;43(6):1483-1490. doi: 10.1111/ijlh.13648. Epub 2021 Jul 16.
5
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.IDH1 和 IDH2 基因突变在新诊断的细胞遗传学正常急性髓系白血病中确定新的分子亚群：癌症和白血病组 B 研究。
J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.
6
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.IDH1 和 IDH2 突变是急性髓系白血病中常见的遗传改变，并且在伴有 NPM1 突变但无 FLT3 内部串联重复的核型正常急性髓系白血病中具有不良预后。
J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.
7
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.伴有 NPM1 突变的 IDH 突变型急性髓系白血病的当代预后：维奈托克治疗的影响。
Am J Hematol. 2022 Nov;97(11):1443-1452. doi: 10.1002/ajh.26694. Epub 2022 Sep 15.
8
IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?急性髓系白血病患者中的异柠檬酸脱氢酶1和异柠檬酸脱氢酶2突变：微小残留病监测的合适靶点？
Clin Biochem. 2018 Nov;61:34-39. doi: 10.1016/j.clinbiochem.2018.08.012. Epub 2018 Aug 31.
9
Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.伴 IDH1 或 IDH2 突变的急性髓系白血病：发生率及临床病理特征。
Am J Clin Pathol. 2011 Jan;135(1):35-45. doi: 10.1309/AJCPD7NR2RMNQDVF.
10
[Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].[急性髓系白血病患者异柠檬酸脱氢酶1和异柠檬酸脱氢酶2突变分析]
Zhonghua Xue Ye Xue Za Zhi. 2012 May;33(5):397-401.

本文引用的文献

1
Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML.基于基因组DNA的新一代测序检测法在急性髓系白血病中检测突变型NPM1可测量残留病的优势。
Blood Adv. 2025 Mar 11;9(5):1069-1077. doi: 10.1182/bloodadvances.2024014490.
2
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.急性髓系白血病异基因移植前可测量的残留突变型异柠檬酸脱氢酶1
Bone Marrow Transplant. 2025 Feb;60(2):154-160. doi: 10.1038/s41409-024-02447-4. Epub 2024 Nov 6.
3
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.
急性髓系白血病异基因移植前可测量的残留突变型异柠檬酸脱氢酶2
Bone Marrow Transplant. 2025 Feb;60(2):144-153. doi: 10.1038/s41409-024-02449-2. Epub 2024 Oct 25.
4
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.维奈托克与低甲基化剂联合治疗初诊急性髓系白血病：301 例连续患者的反应和生存的基因型特征。
Am J Hematol. 2024 Feb;99(2):193-202. doi: 10.1002/ajh.27138. Epub 2023 Dec 10.
5
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.DNA 测序检测造血细胞移植前急性髓系白血病成人患者的残留疾病。
JAMA. 2023 Mar 7;329(9):745-755. doi: 10.1001/jama.2023.1363.
6
Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.在接受异基因移植的 AML 患者中，诊断时和缓解时 IDH1 和 IDH2 突变检测的影响。
Blood Adv. 2023 Feb 14;7(3):436-444. doi: 10.1182/bloodadvances.2021005789.
7
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Venetoclax 和阿扎胞苷在初治伴 IDH1/2 突变的急性髓系白血病患者中的疗效。
Clin Cancer Res. 2022 Jul 1;28(13):2753-2761. doi: 10.1158/1078-0432.CCR-21-3467.
8
Therapy for isocitrate dehydrogenase 2 (IDH2) -mutant acute myeloid leukaemia.异柠檬酸脱氢酶2（IDH2）突变型急性髓系白血病的治疗
Br J Haematol. 2022 Mar;196(6):1348-1352. doi: 10.1111/bjh.17981. Epub 2021 Dec 6.
9
Persistent mutations in remission can predict relapse in patients with acute myeloid leukemia.缓解期持续存在的突变可预测急性髓系白血病患者的复发。
Haematologica. 2019 Feb;104(2):305-311. doi: 10.3324/haematol.2018.191148. Epub 2018 Aug 31.
10
Clinical relevance of mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.在急性髓系白血病随访期间，突变等位基因负担的临床意义。法国 ALFA 集团的一项研究。
Haematologica. 2018 May;103(5):822-829. doi: 10.3324/haematol.2017.183525. Epub 2018 Feb 22.